Chronic lymphocytic leukaemia: Current first-line therapy

Internal Medicine Journal

Volumn 39, Issue 1, 2009, Pages 44-48

  Carney, D A ^a,c   Mulligan, S P ^b,c  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c CLL Australian Research Consortium   (Australia)

Author keywords

Chemoimmunotherapy; Chronic lymphocytic leukaemia; Diagnostic criteria; Fludarabine; Rituximab; Specific subgroups

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; FLAVOPIRIDOL; FLUDARABINE; MITOXANTRONE; MONOCLONAL ANTIBODY; PROTEIN P53; RITUXIMAB;

AUTOIMMUNE HEMOLYTIC ANEMIA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER REGRESSION; CELL TRANSPLANTATION; CHRONIC LYMPHATIC LEUKEMIA; ELDERLY CARE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE DELETION; HEMOLYSIS; HUMAN; IMMUNOLOGICAL TOLERANCE; PRIORITY JOURNAL; PROGNOSIS; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; QUALITY CONTROL; QUALITY OF LIFE; REVIEW; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; VIDARABINE;

EID: 61849132326     PISSN: 14440903     EISSN: 14455994     Source Type: Journal    
DOI: 10.1111/j.1445-5994.2008.01863.x     Document Type: Review

References (31)

1. Dighiero G, Hamblin TJ. Chronic lymphocytic leukaemia. Lancet 2008 371 : 1017 29.
2. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute-Working Group (NCI-WG) 1996 guidelines. Blood 2008 111 : 5446 56. And Erratum. Blood 2008 112 : 5259.
3. Oscier D, Fegan C, Hillmen P, Illidge T, Johnson S, Maguire P et al. Guidelines on the diagnosis and management of chronic lymphocytic leukaemia. Br J Haematol 2004 125 : 294 317.
4. Catovsky D, Richards S, Matutes E, Oscier D, Dyer MJ, Bezares RF et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial. Lancet 2007 370 : 230 39.
5. French Cooperative Group on Chronic Lymphocytic Leukemia. Natural history of stage A chronic lymphocytic leukemia untreated patients. Br J Haematol 1990 76 : 45 60.
6. Moreton P, Kennedy B, Lucas G, Leach M, Rassam SM, Haynes A et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005 23 : 2971 9.
7. Johnson S, Smith AG, Loffler H, Osby E, Juliusson G, Emmerich B et al. Multicentre prospective randomised trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukaemia. The French Cooperative Group on CLL. Lancet 1996 347 : 1432 8.
8. Leporrier M, Chevret S, Cazin B, Boudjerra N, Feugier P, Desablens B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001 98 : 2319 25.
9. Rai KR, Peterson BL, Appelbaum FR, Kolitz J, Elias L, Shepherd I et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000 343 : 1750 57.
10. Eichhorst BF, Busch R, Hopfinger G, Pasold R, Hensel M, Steinbrecher C et al. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006 107 : 885 91.
11. Flinn IW, Neuberg DS, Grever MR, Dewald GW, Bennett JM, Paietta EM et al. Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997. J Clin Oncol 2007 25 : 793 8.
12. Bosch F, Ferrer A, Villamor N, Gine E, Abella MA, Gardella S et al. Combination chemotherapy with fludarabine, cyclophosphamide and mitoxantrone (FCM) induces a high response rate in previously untreated CLL. ASH Annual Meeting Abstracts 2005 106 : 718.
13. Kay NE, Geyer SM, Call TG, Shanafelt TD, Zent CS, Jelinek DF et al. Combination chemoimmunotherapy with pentostatin, cyclophosphamide, and rituximab shows significant clinical activity with low accompanying toxicity in previously untreated B chronic lymphocytic leukemia. Blood 2007 109 : 405 11.
14. Karlsson KA, Strömberg M, Jönsson V, Mulligan SP, Liliemark J, Juliusson G. Cladribine (CdA) Gives longer response duration than fludarabine (F) and high-dose intermittent chlorambucil (Chl) as first-line treatment of symptomatic chronic lymphocytic leukemia (CLL). First Results from the International Randomized Phase III Trial. ASH Annual Meeting Abstracts 2007 110 : 630.
15. Tam CS, O'Brien S, Wierda W, Kantarjian H, Wen S, Do KA et al. Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy chronic lymphocytic leukemia. Blood 2008, 112 : 975 80.
16. Tam CS, Keating MJ. Chemoimmunotherapy of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007 20 : 479 98.
17. Byrd JC, Rai K, Peterson BL, Appelbaum FR, Morrison VA, Kolitz JE et al. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011. Blood 2005 105 : 49 53.
18. Keating MJ, Flinn I, Jain V, Binet JL, Hillmen P, Byrd J et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study. Blood 2002 99 : 3554 61.
19. Hillmen P, Skotnicki AB, Robak T, Jaksic B, Dmoszynska A, Wu J et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007 25 : 5616 23.
20. Wendtner CM, Ritgen M, Schweighofer CD, Fingerle-Rowson G, Campe H, Jäger G et al. Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission-experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL Study Group (GCLLSG). Leukemia 2004 18 : 1093 101.
21. O'Brien SM, Kantarjian HM, Thomas DA, Cortes J, Giles FJ, Wierda WG et al. Alemtuzumab as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia. Cancer 2003 98 : 2657 63.
22. Morrison VA, Peterson BL, Rai KR, Byrd JC, Larson RA. Alemtuzumab Increases Serious Infections in Patients with Previously Untreated Chronic Lymphocytic Leukemia (CLL) Receiving Fludarabine-Based Therapy: A Comparative Analysis of 3 Cancer and Leukemia Group B Studies (CALGB 9011, 9712, 19901). Blood 2007 110 : 756.
23. Lin TS, Donohue KA, Lucas MS, Byrd JC, Bengtson EM, Peterson BL et al. Consolidation therapy with subcutaneous (SC) alemtuzumab results in severe infectious toxicity in previously untreated CLL patients who achieve a complete response (CR) after fludarabine and rituximab (FR) induction therapy: interim safety analysis of the CALGB study 10101. Blood 2007 110 : 755.
24. Del Poeta G, Del Principe MI, Buccisano F, Maurillo L, Capelli G, Luciano F et al. Consolidation and maintenance immunotherapy with rituximab improve clinical outcome in patients with B-cell chronic lymphocytic leukemia. Cancer 2008 112 : 119 28.
25. Bosch F, Muntanola A, Villamor N, Terol MJ, Gonzalez-Barca E, Ribera JM et al. Preliminary results of the combination rituximab, fludarabine, cyclophosphamide and mitoxantrone (R-FCM) followed by rituximab maintenance in previously untreated chronic lymphocytic leukemia (CLL). ASH Annual Meeting Abstracts 2007 110 : 626.
26. Robak T. Novel monoclonal antibodies for the treatment of chronic lymphocytic leukemia. Curr Cancer Drug Targets 2008 8 : 156 71.
27. Auer RL, Gribben J, Cotter FE. Emerging therapy for chronic lymphocytic leukaemia. Br J Haematol 2007 139 : 635 44.
28. Dearden C, Wade R, Else M, Richards S, Milligan D, Hamblin T et al. The prognostic significance of a positive direct antiglobulin test in chronic lymphocytic leukemia: a beneficial effect of the combination of fludarabine and cyclophosphamide on the incidence of hemolytic anemia. Blood 2008 111 : 1820 26.
29. D'Arena G, Cascavilla N. Chronic lymphocytic leukemia-associated autoimmune hemolytic anaemia. Leuk Lymphoma 2007 48 : 1072 80.
30. Osuji NC, Del Giudice I, Matutes E, Wotherspoon AC, Dearden C, Catovsky D. The efficacy of alemtuzumab for refractory chronic lymphocytic leukemia in relation to cytogenetic abnormalities of p53. Haematologica 2005 90 : 1435 6.
31. Dreger P, Corradini P, Kimby E, Michallet M, Milligan D, Schetelig J et al. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: the EBMT transplant consensus. Leukemia 2007 21 : 12 17.